Literature DB >> 11287560

Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells.

K A Weigel-Kelley1, M C Yoder, A Srivastava.   

Abstract

The blood group P antigen, known to be abundantly expressed on erythroid cells, has been reported to be the cellular receptor for parvovirus B19. We have described the development of recombinant parvovirus B19 vectors with which high-efficiency, erythroid lineage-restricted transduction can be achieved (S. Ponnazhagan, K. A. Weigel, S. P. Raikwar, P. Mukherjee, M. C. Yoder, and A. Srivastava, J. Virol. 72:5224-5230, 1998). However, since a low-level transduction of nonerythroid cells could also be detected and since P antigen is expressed in nonerythroid cells, we reevaluated the role of P antigen in the viral binding and entry into cells. Cell surface expression analyses revealed that approximately 75% of primary human bone marrow mononuclear erythroid cells and approximately 31% of cells in the nonerythroid population were positive for P antigen. Two human erythroleukemia cell lines, HEL and K562, and a human promyelocytic leukemia cell line, HL-60, were also examined for P antigen expression and binding and entry of the vector. HEL and K562 cells showed intermediate levels, whereas HL-60 cells demonstrated high levels of expression of P antigen. However, the efficiency of vector binding to these cells did not correlate with P antigen expression. Moreover, despite P antigen positivity and efficient viral binding, HEL, K562, and HL-60 cells could not be transduced with the vector. Low levels of P antigen expression could also be detected in two primary cell types, human umbilical vein endothelial cells (HUVEC) and normal human lung fibroblasts (NHLF). In addition, vector binding occurred in both cell types and was inhibited by globoside, indicating the involvement of P antigen in virus binding to these cells. These primary cells could be efficiently transduced with the recombinant vector. These data suggest that (i) P antigen is expressed on a variety of cell types and is involved in binding of parvovirus B19 to human cells, (ii) the level of P antigen expression does not correlate with the efficiency of viral binding, (iii) P antigen is necessary but not sufficient for parvovirus B19 entry into cells, and (iv) parvovirus B19 vectors can be used to transduce HUVEC and NHLF. These studies further suggest the existence of a putative cellular coreceptor for efficient entry of parvovirus B19 into human cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287560      PMCID: PMC114156          DOI: 10.1128/JVI.75.9.4110-4116.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Different patterns of restriction to B19 parvovirus replication in human blast cell lines.

Authors:  G Gallinella; E Manaresi; E Zuffi; S Venturoli; L Bonsi; G P Bagnara; M Musiani; M Zerbini
Journal:  Virology       Date:  2000-12-20       Impact factor: 3.616

2.  Identification of a novel RNA splicing pattern as a basis of restricted cell tropism of erythrovirus B19.

Authors:  J Brunstein; M Söderlund-Venermo; K Hedman
Journal:  Virology       Date:  2000-09-01       Impact factor: 3.616

3.  Chronic bone marrow failure due to persistent B19 parvovirus infection.

Authors:  G J Kurtzman; K Ozawa; B Cohen; G Hanson; R Oseas; N S Young
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

4.  Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors.

Authors:  J S Bartlett; R Wilcher; R J Samulski
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion.

Authors:  A Puri; P Hug; K Jernigan; P Rose; R Blumenthal
Journal:  Biosci Rep       Date:  1999-08       Impact factor: 3.840

6.  Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3).

Authors:  D Hammache; N Yahi; M Maresca; G Piéroni; J Fantini
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Novel transcription map for the B19 (human) pathogenic parvovirus.

Authors:  K Ozawa; J Ayub; Y S Hao; G Kurtzman; T Shimada; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

8.  Replication of the B19 parvovirus in human bone marrow cell cultures.

Authors:  K Ozawa; G Kurtzman; N Young
Journal:  Science       Date:  1986-08-22       Impact factor: 47.728

9.  Parvovirus-like particles in human sera.

Authors:  Y E Cossart; A M Field; B Cant; D Widdows
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

10.  Experimental parvoviral infection in humans.

Authors:  M J Anderson; P G Higgins; L R Davis; J S Willman; S E Jones; I M Kidd; J R Pattison; D A Tyrrell
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

View more
  39 in total

Review 1.  Pathways of cell infection by parvoviruses and adeno-associated viruses.

Authors:  Maija Vihinen-Ranta; Sanna Suikkanen; Colin R Parrish
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 2.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

3.  CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells.

Authors:  Yong-Mei Guo; Keiko Ishii; Makoto Hirokawa; Hiroyuki Tagawa; Hideaki Ohyagi; Yoshihiro Michishita; Kumi Ubukawa; Junsuke Yamashita; Toshiaki Ohteki; Nobuyuki Onai; Kazuyoshi Kawakami; Weiguo Xiao; Kenichi Sawada
Journal:  Blood       Date:  2010-03-26       Impact factor: 22.113

4.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 5.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

6.  Parvovirus B19 integration into human CD36+ erythroid progenitor cells.

Authors:  Tyler Janovitz; Susan Wong; Neal S Young; Thiago Oliveira; Erik Falck-Pedersen
Journal:  Virology       Date:  2017-08-12       Impact factor: 3.616

7.  Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity.

Authors:  Claudia Bönsch; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Parvovirus B19 genotype specific amino acid substitution in NS1 reduces the protein's cytotoxicity in culture.

Authors:  Violetta Kivovich; Leona Gilbert; Matti Vuento; Stanley J Naides
Journal:  Int J Med Sci       Date:  2010-05-25       Impact factor: 3.738

10.  Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication.

Authors:  Susan Wong; Ning Zhi; Claudia Filippone; Keyvan Keyvanfar; Sachiko Kajigaya; Kevin E Brown; Neal S Young
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.